Resveratrol Inhibits Cardiac Hypertrophy via AMP-activated Protein Kinase and Akt
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Whereas studies involving animal models of cardiovascular disease demonstrated that resveratrol is able to inhibit hypertrophic growth, the mechanisms involved have not been elucidated. Because studies in cells other than cardiomyocytes revealed that AMP-activated protein kinase (AMPK) and Akt are affected by resveratrol, we hypothesized that resveratrol prevents cardiac myocyte hypertrophy via these two kinase systems. Herein, we demonstrate that resveratrol reduces phenylephrine-induced protein synthesis and cell growth in rat cardiac myocytes via alterations of intracellular pathways involved in controlling protein synthesis (p70S6 kinase and eukaryotic elongation factor-2). Additionally, we demonstrate that resveratrol negatively regulates the calcineurin-nuclear factor of activated T cells pathway thus modifying a critical component of the transcriptional mechanism involved in pathological cardiac hypertrophy. Our data also indicate that these effects of resveratrol are mediated via AMPK activation and Akt inhibition, and in the case of AMPK, is dependent on the presence of the AMPK kinase, LKB1. Taken together, our data suggest that resveratrol exerts anti-hypertrophic effects by activating AMPK via LKB1 and inhibiting Akt, thus suppressing protein synthesis and gene transcription.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Resveratrol treatment activates SIRT1, PGC-1α and AMPK [29, 145-148] and inhibits AKT [149] (Figure 4).”
From PGC-1α in aging and anti-aging interventions (2009) · cites this paper as [149]
In the citing paper
“The loss of AMPK activity is believed to be pro-hypertrophic because lines of molecular signaling pathways that control cell growth are attenuated by AMPK activation [197,198,199].”
From AMPK, Mitochondrial Function, and Cardiovascular Disease (2020) · cites this paper as [197]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Activation of the AMP-activated Protein Kinase by the Anti-diabetic Drug Metformin in Vivo
Zou, M.-H., Kirkpatrick, S. S., Davis, B. J., Nelson, J. S., Wiles, W. G., Schlattner, U., Neumann, D., Brownlee, M., Freeman, M. B., & Goldman, M. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404421200 · Cited by 478
RetractedInhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
Resveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy
Molkentin, J. D., Lu, J.-R., Antos, C. L., Markham, B., Richardson, J., Robbins, J., Grant, S. R., & Olson, E. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81573-1 · Cited by 2,566
Shiojima, I. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24682 · Cited by 939
SIRT1 Regulates Hepatocyte Lipid Metabolism through Activating AMP-activated Protein Kinase
Hou, X., Xu, S., Maitland-Toolan, K. A., Sato, K., Jiang, B., Ido, Y., Lan, F., Walsh, K., Wierzbicki, M., Verbeuren, T. J., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802187200 · Cited by 778
Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy
Wilkins, B. J., Dai, Y.-S., Bueno, O. F., Parsons, S. A., Xu, J., Plank, D. M., Jones, F., Kimball, T. R., & Molkentin, J. D. (2004) · Circulation Research · doi:10.1161/01.res.0000109415.17511.18 · Cited by 761
Ouchi, N., Kobayashi, H., Kihara, S., Kumada, M., Sato, K., Inoue, T., Funahashi, T., & Walsh, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310389200 · Cited by 759
Resveratrol stimulates AMP kinase activity in neurons
Dasgupta, B., & Milbrandt, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610068104 · Cited by 723
Adiponectin-mediated modulation of hypertrophic signals in the heart
Shibata, R., Ouchi, N., Ito, M., Kihara, S., Shiojima, I., Pimentel, D. R., Kumada, M., Sato, K., Schiekofer, S., Ohashi, K., et al. (2004) · Nature Medicine · doi:10.1038/nm1137 · Cited by 671
Research works printed but not linked: 2
- Liu, Z., Song, Y., Zhang, X., Liu, Z., Zhang, W., Mao, W., Wang, W., Cui, W., Zhang, X., Jia, X., Li, N., Han, C., and Liu, C. (2005) Clin. Exp. Phar- macol. Physiol. 32, 1049 -1054
- Hou, X., Xu, S., Maitland-Toolan, K. A., Sato, K., Jiang, B., Ido, Y., Lan, F., Walsh, K., Wierzbicki, M., Verbeuren, T. J., Cohen, R. A., and Zang, M. (2008) J. Biol. Chem.
Cited by
Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging
Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03562-9 · Cited by 2,638
Tham, Y. K., Bernardo, B. C., Ooi, J. Y. Y., Weeks, K. L., & McMullen, J. R. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1477-x · Cited by 708
“Pharmacological activation of AMPK has been shown to inhibit the mTOR pathway and attenuate pressure overload-induced hypertrophy (Chan et al. 2004, 2008; Li et al. 2007).”
BackgroundSirtuin 1 and Sirtuin 3: Physiological Modulators of Metabolism
Nogueiras, R., Habegger, K. M., Chaudhary, N., Finan, B., Banks, A. S., Dietrich, M. O., Horvath, T. L., Sinclair, D. A., Pfluger, P. T., & Tschöp, M. H. (2012) · Physiological Reviews · doi:10.1152/physrev.00022.2011 · Cited by 711
“Resveratrol has been shown to be an indirect activator of several proteins such as AMPK, an important enzyme for energy and glucose homeostasis (34, 70, 84, 146, 244, 296, 332).”
BackgroundOxidative Stress in Cardiovascular Diseases
Dubois-Deruy, E., Peugnet, V., Turkieh, A., & Pinet, F. (2020) · Antioxidants · doi:10.3390/antiox9090864 · Cited by 646
“Resveratrol could also reduce phenylephrine-induced protein synthesis and cell hypertrophy in rat cardiac myocytes [71].”
BackgroundSuppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate
Bunse, L., Pusch, S., Bunse, T., Sahm, F., Sanghvi, K., Friedrich, M., Alansary, D., Sonner, J. K., Green, E., Deumelandt, K., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0095-6 · Cited by 539
Resveratrol and Cardiovascular Diseases
Bonnefont-Rousselot, D. (2016) · Nutrients · doi:10.3390/nu8050250 · Cited by 442
“The mechanisms involved include a decrease in oxidative stress, evidenced by an enhanced expression of the antioxidant mitochondrial enzyme Mn-superoxide dismutase (SOD2) [97], an increase in the antioxidant glutathione levels, an activation of eNOS, an inhibition of protein synthesis (AMPK activation and Akt inhibiti…”
BackgroundPillai, V. B., Sundaresan, N. R., Kim, G., Gupta, M., Rajamohan, S. B., Pillai, J. B., Samant, S., Ravindra, P. V., Isbatan, A., & Gupta, M. P. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.077271 · Cited by 419
Caloric restriction, SIRT1 and longevity
Cantó, C., & Auwerx, J. (2009) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.03.008 · Cited by 395
“While some groups have reported that resveratrol action on AMPK is SIRT1 dependent [99, 100], other groups, as well as unpublished data from our lab, suggest that, at least in certain cell types, SIRT1 is dispensable for resveratrol-induced AMPK-activation [97, 101].”
Biological Activities of Stilbenoids
Akinwumi, B., Bordun, K.-A., & Anderson, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030792 · Cited by 373
“explanation of anti-hypertrophic actions of resveratrol is via activation of NO-AMPK signaling [99].”
BackgroundIx, J. H., & Sharma, K. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009080820 · Cited by 348
Zordoky, B. N. M., Robertson, I. M., & Dyck, J. R. B. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.10.016 · Cited by 335
“On the other hand, AMPK activation seems to be essential for the anti-hypertrophic effects of resveratrol, since resveratrol was less effective at inhibiting hypertrophic signaling in AMPK null MEFs [216].”
InfluentialSelf-citationTargeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles
Bonora, M., Wieckowski, M. R., Sinclair, D. A., Kroemer, G., Pinton, P., & Galluzzi, L. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0074-0 · Cited by 294
Cellular and Mitochondrial Effects of Alcohol Consumption
Manzo-Avalos, S., & Saavedra-Molina, A. (2010) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph7124281 · Cited by 293
“This compound inhibits angiotensin II (A-II)-induced cardiomyocyte hypertrophy, because it inhibits production of ROS [154] and reduces 4-hydroxy-2-nonenal (HNE) levels in hearts from spontaneously hypertensive rats [155] maybe by increasing plasma antioxidant capacity [156] and over expression of mitochondrial supero…”
BackgroundCardiovascular effects and molecular targets of resveratrol
Li, H., Xia, N., & Förstermann, U. (2012) · Nitric Oxide · doi:10.1016/j.niox.2011.12.006 · Cited by 287
Resveratrol: from enhanced biosynthesis and bioavailability to multitargeting chronic diseases
Pannu, N., & Bhatnagar, A. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.075 · Cited by 281
Activation and Signaling by the AMP-Activated Protein Kinase in Endothelial Cells
Fisslthaler, B., & Fleming, I. (2009) · Circulation Research · doi:10.1161/circresaha.109.201590 · Cited by 295
Palomer, X., Salvadó, L., Barroso, E., & Vázquez-Carrera, M. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.150 · Cited by 289
“Moreover, SIRT1 overexpression led to deacetylation of PGC-1α [126] and phosphorylation-induced AMPK activation [127].”
BackgroundSulaiman, M., Matta, M. J., Sunderesan, N. R., Gupta, M. P., Periasamy, M., & Gupta, M. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00418.2009 · Cited by 287
“Our finding has a wider implication because impaired SR function and decreased SERCA2a levels are not just limited to diabetic cardiomyopathy but also play a role in end-stage heart failure due to ischemic and dilated cardiomyopathy (30, 33, 34), hypertrophic cardiomyopathy (15, 18), and aging hearts (31), and RSV tre…”
BackgroundAMPK, Mitochondrial Function, and Cardiovascular Disease
Wu, S., & Zou, M.-H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144987 · Cited by 286
AMP-activated protein kinase regulation and biological actions in the heart
Zaha, V. G., & Young, L. H. (2012) · Circulation Research · doi:10.1161/circresaha.111.255505 · Cited by 279
AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation
Gélinas, R., Mailleux, F., Dontaine, J., Bultot, L., Demeulder, B., Ginion, A., Daskalopoulos, E. P., Esfahani, H., Dubois-Deruy, E., Lauzier, B., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02795-4 · Cited by 253
Self-citationResveratrol Prevents the Prohypertrophic Effects of Oxidative Stress on LKB1
Dolinsky, V. W., Chan, A. Y. M., Robillard Frayne, I., Light, P. E., Des Rosiers, C., & Dyck, J. R. B. (2009) · Circulation · doi:10.1161/circulationaha.108.787440 · Cited by 232
Self-citationKiyuna, L. A., Albuquerque, R. P. E., Chen, C.-H., Mochly-Rosen, D., & Ferreira, J. C. B. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.09.019 · Cited by 220
The FoxO Family in Cardiac Function and Dysfunction
Ronnebaum, S. M., & Patterson, C. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135931 · Cited by 206
“Incidentally, it has been demonstrated that the inhibition of hypertrophy by resveratrol treatment is mediated through activation of AMPK, which, as described above, can also promote FoxO activity (96).”
BackgroundResveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice
Dolinsky, V. W., Chakrabarti, S., Pereira, T. J., Oka, T., Levasseur, J., Beker, D., Zordoky, B. N., Morton, J. S., Nagendran, J., Lopaschuk, G. D., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.05.018 · Cited by 206
Self-citationResveratrol as a calorie restriction mimetic: therapeutic implications
Chung, J. H., Manganiello, V., & Dyck, J. R. B. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2012.07.004 · Cited by 192
Self-citationBeauloye, C., Bertrand, L., Horman, S., & Hue, L. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvr034 · Cited by 187
Resveratrol Inhibits mTOR Signaling by Promoting the Interaction between mTOR and DEPTOR
Liu, M., Wilk, S. A., Wang, A., Zhou, L., Wang, R.-H., Ogawa, W., Deng, C., Dong, L. Q., & Liu, F. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.169284 · Cited by 176
Dolinsky, V. W., Jones, K. E., Sidhu, R. S., Haykowsky, M., Czubryt, M. P., Gordon, T., & Dyck, J. R. B. (2012) · The Journal of Physiology · doi:10.1113/jphysiol.2012.230490 · Cited by 174
“2005) and RESV (Chan et al. 2008; Dolinsky et al. 2009) have been shown to activate the energy-sensing kinase AMP-activated protein kinase (AMPK) in the heart.”
BackgroundSelf-citationCalorie restriction and resveratrol in cardiovascular health and disease
Dolinsky, V. W., & Dyck, J. R. B. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.06.010 · Cited by 168
“Increased AMP-activated protein kinase [32,33,62,64] [74,78,86,128,134]”
Self-citationVetterli, L., Brun, T., Giovannoni, L., Bosco, D., & Maechler, P. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.176842 · Cited by 165
Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction
Ikeda, Y., Sato, K., Pimentel, D. R., Sam, F., Shaw, R. J., Dyck, J. R. B., & Walsh, K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.057273 · Cited by 164
Self-citationSIRT1: new avenues of discovery for disorders of oxidative stress
Chong, Z. Z., Shang, Y. C., Wang, S., & Maiese, K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.648926 · Cited by 162
“The anti-hypertrophic effects of SIRT1 and resveratrol treatment also may function via AMPK and the inhibition of Akt (protein kinase B) with subsequent suppression of protein synthesis and gene transcription [87].”
BackgroundMitochondrial SIRT3 and heart disease
Pillai, V. B., Sundaresan, N. R., Jeevanandam, V., & Gupta, M. P. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq250 · Cited by 158
PGC-1α in aging and anti-aging interventions
Anderson, R., & Prolla, T. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.04.005 · Cited by 162
Therapeutic Targeting of Autophagy: Potential and Concerns in Treating Cardiovascular Disease
Orogo, A. M., & Gustafsson, Å. B. (2015) · Circulation Research · doi:10.1161/circresaha.116.303791 · Cited by 166
Kanamori, H., Takemura, G., Goto, K., Tsujimoto, A., Ogino, A., Takeyama, T., Kawaguchi, T., Watanabe, T., Morishita, K., Kawasaki, M., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.11.009 · Cited by 161
“Although we did not trace the resveratrol signaling to AMPK activation in the present study, we did confirm that resveratrol had no effect on the activity of Akt, which is known to associate with AMPK.(23,24) There is also accumulating evidence that resveratrol regulates AMPK activity.”
BackgroundInfluentialSignorelli, P., Munoz-Olaya, J. M., Gagliostro, V., Casas, J., Ghidoni, R., & Fabriàs, G. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.03.020 · Cited by 165
Rimbaud, S., Ruiz, M., Piquereau, J., Mateo, P., Fortin, D., Veksler, V., Garnier, A., & Ventura-Clapier, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026391 · Cited by 142
“In the heart, resveratrol decreases pressure overload-induced hypertrophy and contractile dysfunction [16–20].”
BackgroundThe role of AMPK in cardiomyocyte health and survival
Bairwa, S. C., Parajuli, N., & Dyck, J. R. B. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.07.001 · Cited by 149
Self-citationValidation of anti-aging drugs by treating age-related diseases
Blagosklonny, M. V. (2009) · Aging · doi:10.18632/aging.100034 · Cited by 140
“Resveratrol also indirectly inhibits PI3K/mTOR/S6K pathway [101-105].”
Dull, A.-M., Moga, M. A., Dimienescu, O. G., Sechel, G., Burtea, V., & Anastasiu, C. V. (2019) · Molecules · doi:10.3390/molecules24040667 · Cited by 141
Marino, A., Hausenloy, D. J., Andreadou, I., Horman, S., Bertrand, L., & Beauloye, C. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.02.047 · Cited by 148
“demonstrated by direct activation of AMPK via LKB1 [184].”
BackgroundCardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload
Shimano, M., Ouchi, N., Nakamura, K., van Wijk, B., Ohashi, K., Asaumi, Y., Higuchi, A., Pimentel, D. R., Sam, F., Murohara, T., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108559108 · Cited by 133
“in vivo observations, activation of AMPK by pharmacological reagents, such as metformin or resveratrol, can reduce agoniststimulated protein synthesis and cellular growth in cultured cardiac myocytes (40, 41).”
BackgroundEmerging roles of SIRT1 deacetylase in regulating cardiomyocyte survival and hypertrophy
Sundaresan, N. R., Pillai, V. B., & Gupta, M. P. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.01.008 · Cited by 139
“Resveratrol treatment limits phenylephrine induced hypertrophic response of isolated cardiomyocyte cultures [22].”
BackgroundChang, C.-C., Chang, C.-Y., Wu, Y.-T., Huang, J.-P., Yen, T.-H., & Hung, L.-M. (2011) · Journal of Biomedical Science · doi:10.1186/1423-0127-18-47 · Cited by 125
“Besides, RSV was pronounced to possess both cardioprotective [16-18] and antidiabetic benefits [19,20].”
BackgroundTargeting Cardiovascular Disease With Novel SIRT1 Pathways
Chong, Z. Z., Wang, S., Shang, Y. C., & Maiese, K. (2012) · Future Cardiology · doi:10.2217/fca.11.76 · Cited by 123
“The antihypertrophic effects of resveratrol may also function via activation of AMPK and the inhibition of Akt [115].”
BackgroundRegulation of NAD(P)H oxidases by AMPK in cardiovascular systems
Song, P., & Zou, M.-H. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.01.025 · Cited by 117
AMPK: a therapeutic target of heart failure—not only metabolism regulation
Li, X., Liu, J., Lü, Q., Ren, D., Sun, X., Rousselle, T. V., Tan, Y., & Li, J. (2019) · Bioscience Reports · doi:10.1042/bsr20181767 · Cited by 128
Dolinsky, V. W., Morton, J. S., Oka, T., Robillard-Frayne, I., Bagdan, M., Lopaschuk, G. D., Des Rosiers, C., Walsh, K., Davidge, S. T., & Dyck, J. R. B. (2010) · Hypertension · doi:10.1161/hypertensionaha.110.154732 · Cited by 120
Self-citationWang, C., Wheeler, C. T., Alberico, T., Sun, X., Seeberger, J., Laslo, M., Spangler, E. L., Kern, B., de Cabo, R., & Zou, S. (2011) · AGE · doi:10.1007/s11357-011-9332-3 · Cited by 128
Key Signaling Pathways in Aging and Potential Interventions for Healthy Aging
Yu, M., Zhang, H., Wang, B. Z., Zhang, Y., Zheng, X., Shao, B., Zhuge, Q., & Jin, K. (2021) · Cells · doi:10.3390/cells10030660 · Cited by 131
“In addition, resveratrol could activate AMPK via LKB1 to stimulate mitochondrial biogenesis in neurons, resulting in neuroprotective effects and the inhibition of protein synthesis and genetic transcription by inactivating Akt and, thus, prevent cardiac hypertrophy [58,59].”
BackgroundCoordinated maintenance of muscle cell size control by AMP‐activated protein kinase
Lander, L., Mourner, R., Leclerc, J., Pende, M., Foretz, M., & Viollet, B. (2010) · The FASEB Journal · doi:10.1096/fj.10-155994 · Cited by 108
“Treatment of neonatal rat cardiomyocytes with metformin, AICAR, or resveratrol activated AMPK and inhibited the development of hypertrophy during phenylephrine treatment (33, 34).”
BackgroundSelf-citationLi, S., Zhu, Z., Xue, M., Yi, X., Liang, J., Niu, C. S., Chen, G., Shen, Y., Zhang, H., Jiayong, Z., et al. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.01.019 · Cited by 111
Resveratrol inhibits the mTOR mitogenic signaling evoked by oxidized LDL in smooth muscle cells
de Brito, P. M., Devillard, R., Nègre‐Salvayre, A., Almeida, L. M., Dinis, T. C. P., Salvayre, R., & Augè, N. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.11.011 · Cited by 107
Bruner-Tran, K. L., Osteen, K. G., Taylor, H. S., Sokalska, A., Haines, K., & Duleba, A. J. (2011) · Biology of Reproduction · doi:10.1095/biolreprod.110.086744 · Cited by 101
“Downstream targets of SIRT1 may include, among others, AKT, TRP53, MAPK1/3, and PPAR gamma [11–13].”
BackgroundDihydroceramide desaturase and dihydrosphingolipids: Debutant players in the sphingolipid arena
Fabriàs, G., Munoz-Olaya, J. M., Cingolani, F., Signorelli, P., Casas, J., Gagliostro, V., & Ghidoni, R. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2011.12.002 · Cited by 111
Is AMPK the savior of the failing heart?
Kim, T. T., & Dyck, J. R. B. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.11.001 · Cited by 103
Self-citationResveratrol Attenuates Renal Hypertrophy in Early-Stage Diabetes by Activating AMPK
Ding, D.-F., You, N., Wu, X.-M., Xu, J.-R., Hu, A.-P., Ye, X.-L., Zhu, Q., Jiang, X.-Q., Miao, H., Liu, C., et al. (2010) · American Journal of Nephrology · doi:10.1159/000300388 · Cited by 100
“Studies in cardiac myocyte cells and INS-1E cells have demonstrated that resveratrol modulates cell proliferation mainly through activation of AMPK signaling [”
BackgroundAMP‐activated protein kinase: a core signalling pathway in the heart
Kim, A. S., Miller, E. J., & Young, L. H. (2009) · Acta Physiologica · doi:10.1111/j.1748-1716.2009.01978.x · Cited by 98
“AMPK may prevent pathological hypertrophic growth via reduction in nuclear factor jB and calcineurin-nuclear factor of activated T cells, as well as by reducing cardiac angiotensin II and endothelin levels (Li et al. 2007, Chan et al. 2008).”
BackgroundMethodMetabolic Effects of Metformin in the Failing Heart
Dziubak, A., Wójcicka, G., Wojtak, A., & Bełtowski, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102869 · Cited by 105
“It has been postulated that there are two signaling pathways that play key roles in protein synthesis: eEF-2 (eukaryotic elongation factor 2) pathway and p70S6 (ribosomal protein S6) kinase pathway [109].”
BackgroundInfluentialCardiovascular Protective Effects and Clinical Applications of Resveratrol
Cho, S., Namkoong, K., Shin, M., Park, J., Yang, E., Ihm, J., Thu, V. T., Kim, H. K., & Han, J. (2017) · Journal of Medicinal Food · doi:10.1089/jmf.2016.3856 · Cited by 96
“73–75 Third, resveratrol protects the heart against hypertrophy progression, in part, by affecting cardiac transcription of angiotensin II receptor, AT1a.”
AMPK: An emerging target for modification of injury-induced pain plasticity
Price, T. J., & Dussor, G. O. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.06.060 · Cited by 103
“While there is still ample controversy over the relative contribution of SIRT1 or AMPK for the actions of resveratrol, it is now clear that AMPK plays an important role in resveratrol’s effects [22, 27, 36, 103].”
BackgroundGu, J. F., Fan, Y.-Q., Zhang, H., Pan, J., Yu, J., Zhang, J., & Wang, C. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.02.025 · Cited by 97
The Role of SIRT1 in Diabetic Kidney Disease
Yacoub, R., Lee, K., & He, J. C. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00166 · Cited by 92
“SIRT1 also prevents high glucose-induced mesangial cells hypertrophy by augmenting the AMPK–mTOR signaling pathway (53) and subsequently blocking the activation of Akt signaling (71).”
BackgroundPotential Therapeutic Effects of Natural Heme Oxygenase-1 Inducers in Cardiovascular Diseases
Barbagallo, I. A., Galvano, F., Frigiola, A., Cappello, F., Riccioni, G., Murabito, P., D’Orazio, N., Torella, M., Gazzolo, D., & Volti, G. L. (2012) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4360 · Cited by 105
“Trans-resveratrol attenuates cardiac hypertrophy in spontaneously hypertensive rats via AMP kinase activation (17) and decreases blood pressure in hypertensive rats (97).”
Multifarious molecular signaling cascades of cardiac hypertrophy: Can the muddy waters be cleared?☆
Balakumar, P., & Jagadeesh, G. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.07.003 · Cited by 102
Pyridine Nucleotide Regulation of Cardiac Intermediary Metabolism
Ussher, J. R., Jaswal, J. S., & Lopaschuk, G. D. (2012) · Circulation Research · doi:10.1161/circresaha.111.246371 · Cited by 98
AMP-activated Protein Kinase in the Control of Cardiac Metabolism and Remodeling
Horman, S., Beauloye, C., Vanoverschelde, J., & Bertrand, L. (2012) · Current Heart Failure Reports · doi:10.1007/s11897-012-0102-z · Cited by 97
“Pharmacological AMPK activation in cultured cardiomyocytes modulates p70S6K and eEF2 phosphorylation, inhibits protein synthesis, and prevents cell hypertrophy [40, 41].”
BackgroundResveratrol in cardiovascular disease: what is known from current research?
Wang, H., Yang, Y., Qian, H., Zhang, Q., Xu, H., & Li, J. (2011) · Heart Failure Reviews · doi:10.1007/s10741-011-9260-4 · Cited by 96
“inhibited proliferation at higher dose [25, 90, 92, 104, 111, 127, 129], like a J-curve.”
BackgroundAdrenergic signaling and oxidative stress: a role for sirtuins?
Corbi, G., Conti, V., Russomanno, G., Longobardi, G., Furgi, G., Filippelli, A., & Ferrara, N. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00324 · Cited by 101
Feng, Y., Zhang, Y., & Xiao, H. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9197-5 · Cited by 95
Resveratrol inhibits proliferation, angiogenesis and induces apoptosis in colon cancer cells
Fouad, M. A., Agha, A., Merzabani, M. A., & Shouman, S. A. (2013) · Human & Experimental Toxicology · doi:10.1177/0960327113475679 · Cited by 101
“An effect that was attributed to the potentiation of insulin secretion(44) and sensitivity(45) leads to an increase in the tissue responses.(46,47) However, other investigators like Zhang(37) found that resveratrol inhibits insulin responses in H4IIE cells, HepG2 cells, HEK-293 cells and also in Caenorhabditis elegans…”
BackgroundResveratrol and cardiovascular health – Promising therapeutic or hopeless illusion?
Tang, P. C., Ng, Y.-F., Ho, S., Gyda, M., & Chan, S. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.08.001 · Cited by 95
Novel Role of Silent Information Regulator 1 in Myocardial Ischemia
Yang, Y., Duan, W., Li, Y., Jin, Z., Yan, J., Yu, S., & Yi, D. (2013) · Circulation · doi:10.1161/circulationaha.113.002480 · Cited by 88
Wan, X., Wen, J.-J., Koo, S.-J., Liang, L. Y., & Garg, N. J. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005954 · Cited by 99
“Resveratrol has been shown to induce mitochondrial biogenesis in many tissues [32,33], control pressure overload induced hypertrophy and contractile dysfunction in mice [34,35]; and reverse the ischemia/reperfusion induced loss in renal mitochondrial mass by an increase in the expression of PGC1α and its downstreammed…”
BackgroundMitochondrial quality control in health and cardiovascular diseases
Atici, A. E., Crother, T. R., & Rivas, M. N. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1290046 · Cited by 93
“These molecules have been shown to limit disease severity in multiple rodent CVD models, including Ang-II-induced atherosclerosis (Chen et al., 2015), cardiac hypertrophy (Chan et al., 2008), and diabetic cardiomyopathy (Sulaiman et al., 2010).”
BackgroundEffect of caloric restriction on the SIRT1/mTOR signaling pathways in senile mice
Ma, L., Dong, W., Wang, R., Li, Y., Xu, B., Zhang, J., Zhao, Z., & Wang, Y. (2015) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2015.06.004 · Cited by 88
“Furthermore, resveratrol, which activates sirtuins, stimulates AMP-activated protein kinase to antagonize the mTOR/S6K pathway, and CR may inhibit mTOR by deactivating the insulin/PI-3K pathway (Demidenko and Blagosklonny, 2009; Armour et al., 2009; Chan et al., 2008).”
BackgroundHormesis does not make sense except in the light of TOR-driven aging
Blagosklonny, M. V. (2011) · Aging · doi:10.18632/aging.100411 · Cited by 78
“Resveratrol indirectly antagonizes the mTOR/S6K pathway upstream and downstream [129, 149-153], in part via activation of AMPK and sirtuins [154-160].”
BackgroundWojciechowski, P. W., Juric, D., Louis, X. L., Thandapilly, S. J., Yu, L., Taylor, C. G., & Netticadan, T. (2010) · Journal of Nutrition · doi:10.3945/jn.109.115006 · Cited by 83
“In vitro studies have also shown that cardiomyocyte hypertrophy as a result of exposure to angiotensin-II and endothelin-I, potent hypertrophic agents released in response to elevated blood pressure, was prevented by treatment with resveratrol (19,20).”
BackgroundResveratrol Reverses Functional Chagas Heart Disease in Mice
Vilar-Pereira, G., Carneiro, V. C., dos Santos, H. A. M., Vicentino, A. R. R., Ramos, I. P., Giarola, N. L. L., Feijó, D. F., Meyer‐Fernandes, J. R., Paula-Neto, H. A., Medei, E. H., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005947 · Cited by 83
Quercetin Stimulates Insulin Secretion and Reduces the Viability of Rat INS-1 Beta-Cells
Kittl, M., Beyreis, M., Tumurkhuu, M., Fürst, J., Helm, K., Pitschmann, A., Gaisberger, M., Glasl, S., Ritter, M., & Jakab, M. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000445623 · Cited by 80
Mitochondrial encephalocardio-myopathy with early neonatal onset due to TMEM70 mutation
Honzík, T., Tesařová, M., Mayr, J. A., Hansíková, H., Ješina, P., Bodamer, O. A., Koch, J., Magner, M., Freisinger, P., Huemer, M., et al. (2010) · Archives of Disease in Childhood · doi:10.1136/adc.2009.168096 · Cited by 79
Meng, R., Pei, Z., Zhang, A., Zhou, Y., Cai, X., Chen, B., Guanjie, L., Mai, W., Wei, J., & Dong, Y. (2011) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2011.04.010 · Cited by 79
Cardiac Hypertrophy: From Pathophysiological Mechanisms to Heart Failure Development
Caturano, A., Vetrano, E., Galiero, R., Salvatore, T., Docimo, G., Epifani, R., Alfano, M., Sardu, C., Marfella, R., Rinaldi, L., et al. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2305165 · Cited by 92
Metabolic Shifts during Aging and Pathology
Ma, Y., & Li, J. (2015) · Comprehensive Physiology · doi:10.1002/cphy.c140041 · Cited by 67
Dolinsky, V. W., Rueda-Clausen, C. F., Morton, J. S., Davidge, S. T., & Dyck, J. R. B. (2011) · Diabetes · doi:10.2337/db11-0374 · Cited by 73
Self-citationImpact of Red Wine Consumption on Cardiovascular Health
Liberale, L., Bonaventura, A., Montecucco, F., Dallegri, F., & Carbone, F. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170518100606 · Cited by 79
Sung, M. M. Y., Zordoky, B. N. M., Bujak, A. L., Lally, J., Fung, D., Young, M. E., Horman, S., Miller, E. J., Light, P. E., Kemp, B. E., et al. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv166 · Cited by 76
Self-citationXu, W., Billon, C., Li, H., Wilderman, A. S., Qi, L., Graves, A., Rideb, J. R. D. C., Zhao, Y., Hayes, M. E., Yu, K., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.066542 · Cited by 74
“50,52 In brief, NRVMs were infected with adenovirus containing NFAT-responsive luciferase reporter construct (catalog No.”
MethodTargeting the energy guardian AMPK: another avenue for treating cardiomyopathy?
Li, T. X., Jiang, S., Yang, Z. P., Ma, Z., Yi, W., Wang, D., & Yang, Y. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2407-7 · Cited by 72
“synthesis, featured by decreased levels of p70S6 kinase (p70S6K) and eukaryotic elongation factor-2 (eEF-2) [34].”
Mokni, W., Keravis, T. M., Étienne-Selloum, N., Walter, A., Kane, M. O., Schini‐Kerth, V. B., & Lugnier, C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014227 · Cited by 75
Zhuo, L., Fu, B., Bai, X., Zhang, B., Wu, L., Cui, J., Cui, S., Wei, R., Chen, X., & Cai, G. (2011) · Cellular Physiology and Biochemistry · doi:10.1159/000330077 · Cited by 67
Resveratrol as a therapeutic agent for renal fibrosis induced by unilateral ureteral obstruction
Liang, J., Tian, S.-F., Han, J., & Xiong, P. (2013) · Renal Failure · doi:10.3109/0886022x.2013.844644 · Cited by 67
“Besides, RSV was reported to possess cardioprotective benefits.(10) In particular, Zhao and co-workers have demonstrated that RSV could attenuate As2O3-induced cardiotoxicity.”
Backgroundde Cavanagh, E. M. V., Inserra, F., & Ferder, L. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00459.2014 · Cited by 70
“rat cardiac myocyte hypertrophy by activating AMPK (77) and reducing the activities of 486 ribosomal S6 kinase (S6K) and eEF2 (a translation elongation factor) both of which are 487”
BackgroundAMPKα2 counteracts the development of cardiac hypertrophy induced by isoproterenol
Zarrinpashneh, E., Beauloye, C., Ginion, A., Pouleur, A., Havaux, X., Hue, L., Viollet, B., Vanoverschelde, J., & Bertrand, L. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.09.057 · Cited by 65
“For instance, activation of AMPK was shown to attenuate the development of PKB- [16], phenylephrine- [17] or transaortic constriction-induced hypertrophy [30].”
BackgroundSelf-citationTherapeutic potential of resveratrol in heart failure
Sung, M. M. Y., & Dyck, J. R. B. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12839 · Cited by 63
Self-citationExendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation
Zhou, Y., He, X., Chen, Y., Huang, Y., Wu, L., & He, J. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.09.179 · Cited by 62
Thandapilly, S. J., Louis, X. L., Yang, T., Defries, D. M., Yu, L., Zhang, S., Wigle, J. T., Kardami, E., Zahradka, P. C., Taylor, C. G., et al. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.06.042 · Cited by 69
Sung, M. M. Y., Koonen, D. P. Y., Soltys, C.-L. M., Jacobs, R. L., Febbraio, M., & Dyck, J. R. B. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-010-0720-4 · Cited by 63
“In agreement with our previous findings that AMPK is a major negative regulator of cardiac myocyte cell growth [20–22] and cardiac hypertrophy [20, 23], we also show that the activating phosphorylation status of mTOR, p70S6K, and S6 are all increased in hearts from middle-aged mice fed a HF diet compared with the LF-f…”
BackgroundResultSelf-citation
Metadata
- Authors
- Chan, A. Y. M., Dolinsky, V. W., Soltys, C.-L. M., Viollet, B., Baksh, S., Light, P. E., & Dyck, J. R. B.
- Affiliations
- University of Alberta (CA)
- Corresponding author
- Dyck, Jason R.B.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2008-08
- Volume
- 283
- Issue
- 35
- Pages
- 24194-24201
- ISSN
- 0021-9258 (ISSN-L)
- PMC
- PMC3259789
- OpenAlex
- W2091412980
- Cited by
- 244
- References
- 40
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 5 · 2023: 6 · 2022: 7 · 2021: 8 · 2020: 12 · 2019: 10 · 2018: 16 · 2017: 15 · 2016: 14 · 2015: 19 · 2014: 15 · 2013: 18 · 2012: 21
- FWCI
- 9.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 4445 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Heart and Stroke Foundation of Canada
- European Commission (LSHMCT-2004-005272)
- Agence Nationale de la Recherche
- Fondation pour la Recherche Médicale
- Alberta Heritage Foundation for Medical Research
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- resveratrol, cardiac hypertrophy, AMPK, Akt, LKB1, cardiomyocytes, p70 S6 kinase, elongation factor 2, calcineurin/NFAT signaling, protein synthesis, phenylephrine, gene transcription
- MeSH terms
- Resveratrol, AMP-Activated Protein Kinase Kinases, Animals, Cardiotonic Agents, Cells, Cultured, Enzyme Activation, Enzyme Inhibitors, Cardiomegaly, Multienzyme Complexes, Phenylephrine, Stilbenes, Transcription, Genetic, Protein Biosynthesis, Protein Serine-Threonine Kinases, Peptide Elongation Factor 2, Myocytes, Cardiac, Ribosomal Protein S6 Kinases, 70-kDa, Proto-Oncogene Proteins c-akt, Mice, Rats, AMP-Activated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.